Connection

Eric Meissner to Sofosbuvir

This is a "connection" page, showing publications Eric Meissner has written about Sofosbuvir.
Connection Strength

2.214
  1. Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection. BMC Infect Dis. 2020 Dec 04; 20(1):929.
    View in: PubMed
    Score: 0.706
  2. Characterization of changes in intrahepatic immune cell populations during HCV treatment with sofosbuvir and ribavirin. J Viral Hepat. 2019 03; 26(3):323-328.
    View in: PubMed
    Score: 0.615
  3. Effects of ribavirin/sofosbuvir treatment and ITPA phenotype on endogenous purines. Antiviral Res. 2017 02; 138:79-85.
    View in: PubMed
    Score: 0.134
  4. Dynamic Changes of Post-Translationally Modified Forms of CXCL10 and Soluble DPP4 in HCV Subjects Receiving Interferon-Free Therapy. PLoS One. 2015; 10(7):e0133236.
    View in: PubMed
    Score: 0.122
  5. Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin. J Antimicrob Chemother. 2015 Aug; 70(8):2322-9.
    View in: PubMed
    Score: 0.120
  6. Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients. Hepatology. 2015 Mar; 61(3):790-801.
    View in: PubMed
    Score: 0.118
  7. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clin Invest. 2014 Aug; 124(8):3352-63.
    View in: PubMed
    Score: 0.113
  8. IFNL4-?G genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin. J Infect Dis. 2014 Jun 01; 209(11):1700-4.
    View in: PubMed
    Score: 0.109
  9. Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration. AIDS Res Hum Retroviruses. 2016 May; 32(5):456-62.
    View in: PubMed
    Score: 0.031
  10. Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized Trial. Ann Intern Med. 2015 Dec 15; 163(12):899-907.
    View in: PubMed
    Score: 0.031
  11. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA. 2015 Mar 24-31; 313(12):1232-9.
    View in: PubMed
    Score: 0.030
  12. Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. Lancet. 2015 Mar 21; 385(9973):1107-13.
    View in: PubMed
    Score: 0.029
  13. Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study. Ann Intern Med. 2014 Nov 04; 161(9):634-8.
    View in: PubMed
    Score: 0.029
  14. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA. 2013 Aug 28; 310(8):804-11.
    View in: PubMed
    Score: 0.027
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.